Skip to main content

ABN401

BEST-IN-CLASS cMET TKI For NSCLC Patient

ABN101

Broad Spectrum Prophylaxis
Anti-viral Inhaler Therapeutics

ABN501

Pan-Carcinoma Target Drug

ABN201

Pioneering Antibody Cytokine Fusion Protein Platform

ABN201 is an antibody cytokine fusion protein(ACFP) which adds antibody targeting ability to ABN101 with effective anticancer activity. It has a potential to be developed as an anticancer platform with greater application than ADC. ABN201 is targeting solid cancer and combination therapy with ABN401 and EGFR inhibitors are being studied.

Anticancer mechanisms of action of antibody-IFNβ mutein fusion protein

Direct Cytotoxicity

  • IFNb localization to tumor
  • Direct tumor cell killing through IFN-receptor induced death receptor mediated apoptosis

Indirect Cytotoxicity

  • Tumor derived antigen cross-presentation of CD8α+ DC, stimulated by IFNb
  • Activation of antigen-specific cytotoxic T-cell
  • Tumor cell death

Enhanced efficacy and reduced systemic toxicity